Nexalin Technology Awarded Key Patent Related To Gen-3 HALO Clarity
Nexalin Technology Awarded Key Patent Related To Gen-3 HALO Clarity
Mark White, CEO of Nexalin Technology, stated, "This method of use patent award marks a major achievement for the Company and follows another recent patent covering our core technology. These patents extend through 2040 and are a critical element of our overall strategy, given the mounting clinical data supporting the benefits of our noninvasive, deep frequency brain stimulation technology in the fields of insomnia, depression, and anxiety. A key differentiator for our new Gen-3 HALO Clarity is that, for the first time, it enables patients to receive this treatment in the privacy of their own homes with remote monitoring by a physician in Nexalin's Virtual Clinic."
Nexalin Technology首席执行官马克·怀特表示：“这项使用方法专利奖标志着公司的一项重大成就，也是继最近又一项涵盖我们核心技术的专利之后。这些专利有效期至2040年，是我们总体战略的关键要素，因为越来越多的临床数据支持我们的无创深频脑刺激技术在失眠、抑郁和焦虑领域的益处。我们的新Gen-3 HALO Clarity的一个关键差异化因素是，它首次使患者能够在自己的家中私密地接受这种治疗，并由Nexalin虚拟诊所的医生进行远程监控。”